MEI Pharma, Inc. (MEIP)
- Previous Close
2.1900 - Open
2.1600 - Bid --
- Ask --
- Day's Range
2.0750 - 2.2399 - 52 Week Range
1.4600 - 4.1000 - Volume
1,700 - Avg. Volume
8,758 - Market Cap (intraday)
14.924M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-4.7500 - Earnings Date May 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 16, 2023
- 1y Target Est
--
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
meipharma.comRecent News: MEIP
View MorePerformance Overview: MEIP
Trailing total returns as of 5/30/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MEIP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MEIP
View MoreValuation Measures
Market Cap
14.92M
Enterprise Value
-23.42M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.76
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.56%
Return on Equity (ttm)
-89.74%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-31.66M
Diluted EPS (ttm)
-4.7500
Balance Sheet and Cash Flow
Total Cash (mrq)
20.47M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-17.99M